Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates
Feb 28, 2018 12:01 pm UTC| Business
Galafold Expansion Continues with 360+ Fabry Patients Treated Today - on Track to Achieve FY18 Revenue Guidance of $75M-$85M Significant Progress Across Pompe Clinical, Regulatory and Manufacturing Activities -...
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
Feb 28, 2018 12:01 pm UTC| Business
Key updates Runway into the second half of 2019: cash of €48.0 million at year-end expected to fund operations through anticipated clinical data readouts in three different programs.First patient dosed in the Phase 1/2...
Lexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS Conference
Feb 28, 2018 12:01 pm UTC| Business
THE WOODLANDS, Texas, Feb. 28, 2018 -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be presented at the upcoming 15th Annual...
Feb 28, 2018 12:01 pm UTC| Business
WEST FARGO, N.D. and WINNIPEG, Manitoba, Feb. 28, 2018 -- Titan Machinery Inc. (Nasdaq:TITN) announced today a strategic alliance that brings Farmers Edge precision digital solutions to growers across Titan’s...
Feb 28, 2018 12:01 pm UTC| Business
STAMFORD, Conn., Feb. 28, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively...
Feb 28, 2018 12:01 pm UTC| Business
RANCHO CORDOVA, Calif., Feb. 28, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho,...
Novelion Therapeutics Observes Rare Disease Day
Feb 28, 2018 12:00 pm UTC| Business
VANCOUVER, British Columbia, Feb. 28, 2018 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today...